Background: Brain metastases commonly occur in non–small cell lung cancer (NSCLC), and
patient prognosis is poor. Erlotinib, a specific inhibitor of epidermal growth factor receptor …

The clinical efficacy of gefitinib, a tyrosine kinase inhibitor of epidermal growth factor
receptor (EGFR), on brain metastases (BMs) from non–small-cell lung cancer (NSCLC) was …

Background Lung cancer is the most common type of cancer to spread to the brain (brain
metastasis [BM]). This study assessed the effect of epidermal growth factor receptor (EGFR) …

Abstract Objective Tyrosine kinase inhibitors (TKIs) is the first-line treatment for EGFR-
positive non-small cell lung cancer (NSCLC); however, its applicability to patients with wild …

The growth of genotype‐directed targeted therapies, such as inhibitors of the epidermal
growth factor receptor (EGFR), has revolutionized treatment for some patients with …

Background Non-small cell lung cancer (NSCLC) with brain metastasis (BM) harboring an
epidermal growth factor receptor (EGFR) mutation shows good response to tyrosine kinase …

We proposed to compare the outcomes of first‐line epidermal growth factor receptor–
tyrosine kinase inhibitor (EGFR‐TKI) alone with EGFR‐TKI plus whole‐brain radiotherapy …

Controversial value of prophylactic cranial irradiation (PCI) in NSCLC in terms of survival
benefit prompted us to explore the possible risk factors for brain metastasis (BM) during the …

Objective Brain metastasis is frequently found in patient with advanced non-small cell lung
cancer. Gefitinib is a inhibitor of epidermal growth factor receptor and can be used for the …

Preferable treatments for epidermal growth factor receptor (EGFR)-mutant non-small cell
lung cancer (NSCLC) with brain metastasis are elusive. The study intended to estimate the …